ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,702.55
      -0.19%
      US Tech 100
      19,287.60
      -0.24%
      Dow Jones
      42,063.36
      0.09%
      Brent Oil
      74.135
      0.00%
      Bitcoin
      62,998.48
      -0.32%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Verastem Inc (VSTM)

      7. Verastem Inc (VSTM) News

      VSTM

      Verastem (VSTM)

      Verastem Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VSTM
      DateTimeSourceHeadlineSymbolCompany
      09/20/20246:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      09/20/20246:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      09/18/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      09/18/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      09/10/20244:05PMBusiness WireVerastem Oncology to Present at the 2024 Cantor Global Healthcare ConferenceNASDAQ:VSTMVerastem Inc
      09/10/20247:30AMBusiness WireVerastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual MeetingNASDAQ:VSTMVerastem Inc
      09/03/20247:30AMBusiness WireVerastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024NASDAQ:VSTMVerastem Inc
      08/08/20244:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VSTMVerastem Inc
      08/08/20244:05PMBusiness WireVerastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business UpdatesNASDAQ:VSTMVerastem Inc
      07/29/20244:01PMBusiness WireVerastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic CancerNASDAQ:VSTMVerastem Inc
      07/25/20248:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
      07/24/20245:06PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VSTMVerastem Inc
      07/23/202411:20PMBusiness WireVerastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded WarrantsNASDAQ:VSTMVerastem Inc
      07/23/20244:33PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VSTMVerastem Inc
      07/23/20244:05PMBusiness WireVerastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded WarrantsNASDAQ:VSTMVerastem Inc
      07/23/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
      07/12/20247:30AMBusiness WireVerastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet TherapeuticsNASDAQ:VSTMVerastem Inc
      07/11/20247:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      07/08/20247:30AMBusiness WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VSTMVerastem Inc
      07/01/20247:30AMBusiness WireVerastem Oncology Announces Addition to Russell 3000® and Russell Microcap® IndexesNASDAQ:VSTMVerastem Inc
      05/24/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
      05/24/20247:00AMBusiness WireVerastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
      05/23/20245:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
      05/23/20245:01PMBusiness WireVerastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​NASDAQ:VSTMVerastem Inc
      05/09/20244:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VSTMVerastem Inc
      05/09/20244:02PMBusiness WireVerastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesNASDAQ:VSTMVerastem Inc
      05/07/20247:30AMBusiness WireVerastem Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:VSTMVerastem Inc
      04/18/20244:05PMBusiness WireVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerNASDAQ:VSTMVerastem Inc
      04/04/20247:30AMBusiness WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VSTMVerastem Inc
      03/18/20247:00AMBusiness WireGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
       Showing the most relevant articles for your search:NASDAQ:VSTM

      Your Recent History

      COIN
      MACCCUST
      Magic metaverse coin
      Delayed Upgrade Clock